This site is intended for healthcare professionals

Allarity Therapeutics provides update on dovitinib program for renal cell carcinoma.

Read time: 1 mins
Last updated:26th Oct 2020
Published:24th Oct 2020
Allarity Therapeutics A/S announced several updates related to its planned filing of a new drug application (NDA) with the FDA for dovitinib, a pan-tyrosine kinase inhibitor (TKI) that is one of Allarity’s priority programs.
Condition: Renal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest